Provectus Biopharmaceuticals (PVCT) CEO holds 52.4M shares, 11.61% stake

Rhea-AI Filing Summary

An amended beneficial ownership report states that Edward Pershing, Chairman and CEO of Provectus Biopharmaceuticals, Inc., beneficially owns 52,441,275 shares of common stock, representing 11.61% of the company’s common shares. The percentage is based on 420,279,879 shares outstanding as of June 30, 2026 plus shares underlying his options, preferred stock and convertible notes.

Pershing’s position includes directly held stock, retirement plan holdings, 16,980,144 stock options exercisable within 60 days, and common shares issuable from Series D‑1 convertible preferred and remaining notes. The issuer has issued to him an aggregate $7,512,500 principal amount of secured convertible promissory notes since 2018; $6,642,500 has converted into Series D‑1 preferred at $2.862 per share, including recent automatic conversions in May and June 2026 and a new $15,000 note purchase on May 28, 2026.

Key Figures

Beneficial ownership: 52,441,275 shares of Common Stock Ownership percentage: 11.61% Shares outstanding: 420,279,879 shares of Common Stock +5 more

8 metrics

Beneficial ownership 52,441,275 shares of Common Stock Aggregate shares beneficially owned by Edward Pershing as of Amendment No. 3

Ownership percentage 11.61% Percent of Provectus common stock beneficially owned by Edward Pershing

Shares outstanding 420,279,879 shares of Common Stock Common shares outstanding as of June 30, 2026 used in ownership calculation

Convertible notes issued $7,512,500 principal amount Aggregate principal of secured convertible promissory notes issued to Edward Pershing from April 13, 2018 to May 28, 2026

Converted notes principal $6,642,500 principal amount Principal amount of notes plus interest converted into 2,866,761 Series D-1 preferred at $2.862 per share

Series D-1 preferred held 2,866,761 shares Series D-1 Convertible Preferred Stock held by Edward Pershing, convertible into 28,667,610 common shares

Options exercisable 16,980,144 shares Common shares issuable upon exercise of stock options currently exercisable or exercisable within 60 days

Remaining notes principal $908,554 principal amount Convertible promissory notes held by Edward Pershing, convertible with interest into 363,314 Series D-1 preferred and 3,633,141 common shares

Key Terms

beneficially owns, Series D-1 Convertible Preferred Stock, secured convertible promissory notes, dispositive power, +1 more

5 terms

beneficially owns financial

"the Reporting Person beneficially owns an aggregate of 52,441,275 shares"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Series D-1 Convertible Preferred Stock financial

"shares of the Issuer's Series D-1 Convertible Preferred Stock, par value $0.001 per share"

secured convertible promissory notes financial

"issued an aggregate of $7,512,500 principal amount of secured convertible promissory notes"

A secured convertible promissory note is a written IOU where a borrower promises to repay money that is backed by specific assets (secured) and includes an option for the lender to convert the debt into company shares (convertible). Think of it as lending money against collateral with a choice to take the borrower’s stock instead of cash; investors watch these instruments because they change who gets paid first in a liquidation and can dilute existing shareholders if converted to equity.

dispositive power financial

"The Reporting Person has sole voting and dispositive power over"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Issuer's 2025 Financing financial

"purchased a convertible promissory note from the Issuer in the principal amount of $15,000 pursuant to the Issuer's 2025 Financing"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/22/2026 - 03:04 PM Accepted by SEC EDGAR 07/22/2026 - 03:04 PM Learn about SEC filing dates

FAQ

What stake does Edward Pershing report in Provectus Biopharmaceuticals (PVCT)?

Edward Pershing reports beneficial ownership of 52,441,275 shares of Provectus Biopharmaceuticals common stock, representing 11.61% of the company’s outstanding common shares. This total includes directly held stock, retirement plan holdings, options, convertible preferred stock and shares underlying remaining convertible notes.

How is Edward Pershing's 11.61% ownership in PVCT calculated?

The 11.61% figure is calculated using 420,279,879 Provectus common shares outstanding as of June 30, 2026, plus 28,667,610 shares from Series D-1 preferred, 3,633,141 shares from preferred issuable via notes, and 16,980,144 shares from exercisable stock options held by Edward Pershing under this amended Schedule 13D.

What financing has Edward Pershing provided to Provectus Biopharmaceuticals (PVCT)?

Provectus has issued Edward Pershing secured convertible promissory notes with aggregate principal of $7,512,500 between April 13, 2018 and May 28, 2026. Of this, $6,642,500 principal plus interest has converted into 2,866,761 Series D-1 preferred shares at $2.862 per share.

What convertible preferred stock does Edward Pershing hold in PVCT?

Edward Pershing holds 2,866,761 shares of Provectus Series D-1 Convertible Preferred Stock, which can be converted into 28,667,610 common shares. He may receive another 363,314 Series D-1 shares from $908,554 of remaining notes, convertible into 3,633,141 common shares under the terms described in this amendment.

What recent PVCT transactions did Edward Pershing report in this Schedule 13D/A?

Within sixty days of this amendment, Edward Pershing reported several note conversions and a new note purchase. Notes of $50,000, $60,000, $85,000 and $25,000 automatically converted into Series D-1 preferred, and he purchased an additional $15,000 convertible note on May 28, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

PROVECTUS BIOPHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

74373P108

(CUSIP Number)

Heather Raines
800 S. Gay Street, Suite 1610,
Knoxville, TN, 37929
(866) 594-5999

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/30/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 74373P108

1

Name of reporting person

Pershing Edward

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 52,278,925.00
8	Shared Voting Power 162,350.00
9	Sole Dispositive Power 52,278,925.00
10	Shared Dispositive Power 162,350.00

11

Aggregate amount beneficially owned by each reporting person

52,441,275.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

11.61 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(1) Sole voting and dispositive power includes 176,000 shares of common stock owned directly by the Reporting Person, 2,822,030 shares of common stock owned by the Reporting Person through a retirement plan, 16,980,144 shares of common stock issuable upon exercise of stock options that are currently exercisable or exercisable within 60 days, 28,667,610 shares of common stock issuable upon conversion of 2,866,761 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person, and 3,633,141 shares of common stock issuable upon conversion of 363,314 shares of Series D-1 Convertible Preferred Stock which are issuable upon conversion of $908,554 aggregate principal amount and accrued interest of convertible promissory notes held by the Reporting Person. (2) Shared voting and dispositive power includes 60,600 shares of common stock owned by the Reporting Person's spouse, 16,500 shares of common stock owned by the Reporting Person's spouse through a retirement plan, 3,750 shares of common stock held as custodian for a grandchild, and 81,500 shares of common stock owned by Mr. Pershing's Foundation, a nonprofit corporation of which the Reporting Person is an affiliate.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: PROVECTUS BIOPHARMACEUTICALS, INC.
(c)	Address of Issuer's Principal Executive Offices: 800 S. GAY STREET, SUITE 1610, KNOXVILLE, TENNESSEE , 37929.
Item 1 Comment: This Amendment No. 3 ("Amendment No. 3") amends and supplements the Statement on Schedule 13D filed by Edward Pershing (the "Reporting Person") with the Securities and Exchange Commission (the "SEC") on July 3, 2024 (the "Original Schedule 13D"), as amended by Amendment No. 1 filed with the SEC on December 6, 2024 ("Amendment No. 1"), as amended by Amendment No. 2 filed with the SEC on December 1, 2025 ("Amendment No. 2," and together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, and this Amendment No. 3, the "Schedule 13D") with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Provectus Biopharmaceuticals, Inc. (the "Issuer"). Capitalized terms used herein and not otherwise defined in this Amendment No. 3 shall have the meanings set forth in the Original Schedule 13D. This Amendment No. 3 amends Items 3 and 5(a), (b) and (c), as set forth below.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows: The Issuer has issued an aggregate of $7,512,500 principal amount of secured convertible promissory notes (the "Notes") to the Reporting Person on various dates from April 13, 2018 to May 28, 2026. On various dates from April 13, 2018 to June 26, 2026, $6,642,500 principal amount of the Notes plus interest converted into 2,866,761 shares of the Issuer's Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Convertible Preferred Stock") at a conversion price of $2.862 per share in accordance with the terms of the Notes. In addition, on February 9, 2026, the Reporting Person purchased 34,940 shares of Series D-1 Convertible Preferred Stock at a purchase price of $2.862 per share in a private transaction. In addition, on November 22, 2024, the Reporting Person purchased 80,365 shares of Series D-1 Convertible Preferred Stock at a purchase price of $2.862 per share in a private transaction. The 2,866,761 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person are convertible into 28,667,610 shares of Common Stock. The Reporting Person currently holds $908,554 aggregate principal amount of Notes that, along with accrued interest, are convertible into 363,314 shares of Series D-1 Convertible Preferred Stock, which are convertible into 3,633,141 shares of Common Stock. The remainder of the shares of Common Stock held by the Reporting Person were acquired in other market transactions from 2006 to 2016. The Reporting Person acquired the Issuer securities reported herein using his personal funds, including funds borrowed from a financial institution using a personal line of credit that is not secured by the Issuer securities owned by the Reporting Person.
Item 5.	Interest in Securities of the Issuer
(a)	Paragraph (a) of Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: As of the date of this Amendment No. 3, the Reporting Person beneficially owns an aggregate of 52,441,275 shares of Common Stock, or 11.61% of the Issuer's outstanding shares of Common Stock. The beneficial ownership percentages used in this Schedule 13D are calculated based on a total of 420,279,879 shares of Common Stock outstanding as of June 30, 2026 plus (i) 28,667,610 shares of Common Stock issuable upon conversion of 2,866,761 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person; (ii) 3,633,141 shares of Common Stock issuable upon conversion of 363,314 shares of Series D-1 Convertible Preferred Stock which are issuable upon conversion of $908,554 aggregate principal amount and accrued interest of convertible promissory notes held by the Reporting Person; and (iii) 16,980,144 shares of Common Stock issuable upon exercise of stock options that are currently exercisable or exercisable within 60 days.
(b)	Paragraph (b) of Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Person has sole voting and dispositive power over (i) 176,000 shares of Common Stock owned directly by the Reporting Person, (ii) 2,822,030 shares of Common Stock owned by the Reporting Person through a retirement plan, (iii) 28,667,610 shares of Common Stock issuable upon conversion of 2,866,761 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person, (iv) 3,633,141 shares of Common Stock issuable upon conversion of 363,314 shares of Series D-1 Convertible Preferred Stock which are issuable upon conversion of $908,554 aggregate principal amount and accrued interest of convertible promissory notes held by the Reporting Person; and (v) 16,980,144 shares of Common Stock issuable upon exercise of stock options that are currently exercisable or exercisable within 60 days. The Reporting Person has shared voting and dispositive power over 60,600 shares of Common Stock owned by the Reporting Person's spouse, 16,500 shares of Common Stock owned by the Reporting Person's spouse through a retirement plan, 3,750 shares of Common Stock held as custodian for a grandchild, and 81,500 shares of Common Stock owned by Mr. Pershing's Foundation, a nonprofit corporation of which the Reporting Person is an affiliate.
(c)	Paragraph (c) of the Schedule 13D is being amended and supplemented by the addition of the following: The following transactions were effected during the sixty days prior to Amendment No. 3: On June 5, 2026, a convertible promissory note in the aggregate principal amount of $25,000 held by the Reporting Person automatically converted into 9,436 shares of the Issuer's Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the convertible note. On May 28, 2026, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $15,000 pursuant to the Issuer's 2025 Financing. On May 26, 2026, a convertible promissory note in the aggregate principal amount of $85,000 held by the Reporting Person automatically converted into 32,089 shares of the Issuer's Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the convertible note. On May 15, 2026, a convertible promissory note in the aggregate principal amount of $60,000 held by the Reporting Person automatically converted into 32,089 shares of the Issuer's Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the convertible note. On May 7, 2026, a convertible promissory note in the aggregate principal amount of $50,000 held by the Reporting Person automatically converted into 18,876 shares of the Issuer's Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the convertible note.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Pershing Edward

Signature:	/s/ Edward Pershing
Name/Title:	Edward Pershing, Chairman and CEO
Date:	07/22/2026